Lupin Pharma Canada, Endoceutics enter partnership for commercialization of Intrarosa

Published On 2021-03-10 06:30 GMT | Update On 2021-03-10 06:30 GMT

Mumbai, Quebec, Canada: Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, has recently announced a partnership with Endoceutics, a women's health focused innovative Canadian biotech company, to commercialize Intrarosa in Canada.

Intrarosa is Endoceutic's flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone.

Commenting on the partnership, Dr. Sofia Mumtaz, President, Lupin Pharma Canada said, "We are very pleased to partner with Endoceutics to bring this long-awaited innovative product to the Canadian market. Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs."

"We are very excited to be working closely with Lupin in Canada. We believe they are the right partner to successfully bring Intrarosa to the market," commented Dennis Turpin, President and Chief Executive Officer, Endoceutics.

It is estimated that over 50% of postmenopausal women suffer from the symptoms of vulvovaginal atrophy and that less than 10% of these women are treated with prescription medicines.

Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.

The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Lupin Pharma Canada, Endoceutics enter partnership for commercialization of Intrarosa

Similar News

After Cough Syrup Deaths, CDSCO Tightens Oversight on Drug Testing Compliance

Exemed Pharma's Empagliflozin-Vildagliptin Combo Rejected by CDSCO Panel Over Questionable Clinical Use

Ravenbhel Gets SEC Nod to Market Bilastine, Montelukast FDC, Phase IV Trial Mandated

Drugs Control Officials Caught Taking Rs 20,000 Bribe in Telangana

Contaminated Cough Syrup horror: Centre proposes license cancellation of Coldrif maker, Tamil Nadu FDA yet to act

Himachal, UP Join States Banning Coldrif Cough Syrup After MP Deaths

Toxic syrup tragedy: MP police hunt pharma co owner after child deaths

Not of Standard Quality: Gujarat orders suspension of production at two pharma cos